Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 107 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Bakhriansyah M, Souverein PC, de Boer A, Klungel OH. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case–control study. Pharmacoepidemiol Drug Saf 2017;26:1141-8. [Ref.ID 102084]
2. Cita con resumen
Casassus B. Contraception implant removed from global market. Lancet 2017;390:1576. [Ref.ID 102079]
3. Cita con resumen
Anónimo. Trametinib (Mekinist): risk of gastrointestinal perforation and colitis . Drug Safety Update 2016;9:2. [Ref.ID 100029]
4.Enlace a cita original
6.Tiene citas relacionadas Cita con resumen
Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79. [Ref.ID 96000]
7.Tiene citas relacionadas Cita con resumen
Griffin MR. High-dose non-steroidal anti-inflammatories: painful choices. Lancet 2013;382:746-8. [Ref.ID 95994]
8.Tiene citas relacionadas Cita con resumen
Bhatt DL, Laine L, Cannon CP. Clopidogrel with or without omeprazole in coronary disease. The authors reply. N Engl J Med 2011;364:682. [Ref.ID 90219]
9.Tiene citas relacionadas Cita con resumen
Juurlink DN. Clopidogrel with or without omeprazole in coronary disease. N Engl J Med 2011;364:681-2. [Ref.ID 90218]
10.Tiene citas relacionadas Cita con resumen
Sadek A, Ford AC. Clopidogrel with or without omeprazole in coronary disease. N Engl J Med 2011;364:681. [Ref.ID 90217]
11.Tiene citas relacionadas
Hayes DF. Bevacizumab treatment for solid tumors. Boon or bust?. JAMA 2011;305:506-8. [Ref.ID 90151]
12.Tiene citas relacionadas Cita con resumen
Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients. A meta-analysis. JAMA 2011;305:487-94. [Ref.ID 90150]
13.Tiene citas relacionadas Cita con resumen
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP, for the COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17. [Ref.ID 89643]
14. Cita con resumen
Anónimo. Méthylnaltrexone: perforations digestives. Prescrire 2010;30:742. [Ref.ID 89215]
15. Cita con resumen
Anónimo. Everolimus and pazopanib: two new drugs for renal cell cancer. Med Lett Drugs Ther 2010;52:33-4. [Ref.ID 88491]
16. Cita con resumen
Anónimo. Erlotinib: perforations digestives, éruptions bulleuses. Prescrire 2009;29:826. [Ref.ID 87136]
17. Cita con resumen
Anónimo. Erlotinib warning. JAMA 2009;301:2542. [Ref.ID 86123]
18. Cita con resumen
Maestri E, Marata AM, Capelli O, Magnano L, Formoso G, Magrini N. Vecchi e nuovi bisfosfonati nella prevenzione delle fratture legate ad osteoporosi. Informazioni sui Farmaci 2008;32:94-101. [Ref.ID 84695]
19.Enlace a cita original Cita con resumen
Patterson MK, Castellsagué J, Walker AM. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. Pharmacoepidemiol Drug Saf 2008;17:982-8. [Ref.ID 84310]
20. Cita con resumen
Anónimo. Sorafénib: perforations digestives. Prescrire 2008;28:664. [Ref.ID 83943]
Seleccionar todas
 
 1 a 20 de 107 siguiente >>